Drug Details

General Information of the Drug (ID: DR4698)
Name
Anti-CD25 monoclonal antibody
Synonyms
Humanized anti-Tac antibody (HAT)
    Click to Show/Hide
Molecular Type
Antibody
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Approved [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Flavopiridol      Dysoxylum binectariferum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model FCCH1043 CVCL_M518 Adult T acute lymphoblastic leukemia Homo sapiens
MT-2 CVCL_2631 Healthy Homo sapiens
HuT 102 CVCL_3526 Mycosis fungoides and Sezary syndrome Homo sapiens
                    In-vivo Model The xenograft model was established by intraperitoneal injection of 1.5*107 MET-1 cells into SCID/NOD mice.
                    Experimental
                    Result(s)		 Combination of the flavopiridol and anti-CD25 monoclonal antibody dramatically enhanced the antitumor effect.
Target and Pathway
Target(s) Protein lin-28 homolog A (LIN28A)  Molecule Info  [3]
Protein lin-28 homolog B (LIN28B)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website.
Reference 2 Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood. 2005 Feb 1;105(3):1231-6.
Reference 3 In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma. Eur J Pharmacol. 2021 Jan 15;891:173757.
 Download Picture         KEGG Link